|Day Low/High||20.56 / 21.87|
|52 Wk Low/High||18.18 / 56.70|
Investors in Portola Pharmaceuticals, Inc. saw new options begin trading this week, for the November 16th expiration.
Investors in Portola Pharmaceuticals, Inc. saw new options begin trading this week, for the January 2021 expiration.
Big insider purchases at Portola Pharmaceuticals and Alta Mesa Resources could be revealing.
Investors in Portola Pharmaceuticals, Inc. saw new options begin trading this week, for the October 19th expiration.
Jim Cramer weighs in on Diamondback Energy, Illinois Tool Works, Xerox, PetMed Express, STMicroelectronics, Booking and more.
Upcoming earnings? Optimistic spin on trade? Tech rally? Jim Cramer's got the game plan for next week and he tells investors to keep their cool.
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Portola Pharmaceuticals, Inc. , where a total of 6,062 contracts have traded so far, representing approximately 606,200 underlying shares.
Investors in Portola Pharmaceuticals, Inc. saw new options begin trading this week, for the December 21st expiration.
Event Scheduled for Monday, March 12, 2018 at 12:30 p.m. ET
Company to Host Conference Call on Tuesday, February 20, 2018, at 5:00 p.m. ET
The most recent short interest data has been released for the 01/12/2018 settlement date, which shows a 553,785 share increase in total short interest for Portola Pharmaceuticals, Inc. , to 4,455,929, an increase of 14.19% since 12/29/2017.
Bevyxxa Available to Patients in January 2018
The South San Francisco, Calif.-based firm said after the market close on Tuesday that the FDA has extended the review period for the company's prior approval supplement for Bevyxxa (betrixaban).
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.